Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MK5684 versus alternative novel hormonal agent in metastatic castration-resistant prostate cancer after one prior NHA
PACTR202411804967234Phase 3Not yet recruiting
- Sponsor
- MSD
- Start
- Jul 2025
- Countries
- 2
01
Overview
Phase 3, randomised trial in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by MSD. Planned start Jul 2025; status: not yet recruiting.
02
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on PACTR202411804967234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202411804967234.